Reference | 1: Ushigome E, Matsumoto S, Oyabu C, Ushigome H, Yokota I, Hasegawa G, Nakamura
N, Tanaka M, Yamazaki M, Fukui M. Olmesartan with azelnidipine versus with
trichlormethiazide on home blood pressure variability in patients with type II
diabetes mellitus. J Am Soc Hypertens. 2017 Mar;11(3):140-147. doi:
10.1016/j.jash.2016.12.004. Epub 2016 Dec 22. PubMed PMID: 28089902.
<br>
2: Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y. Comparison
of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with
Hypertension: The COAT Randomized Controlled Trial. PLoS One. 2015 May
4;10(5):e0125519. doi: 10.1371/journal.pone.0125519. eCollection 2015. PubMed
PMID: 25938807; PubMed Central PMCID: PMC4418830.
<br>
3: Schulze S, Reinhardt S, Freese C, Schmitt U, Endres K. Identification of
trichlormethiazide as a Mdr1a/b gene expression enhancer via a dual
secretion-based promoter assay. Pharmacol Res Perspect. 2015 Feb;3(1):e00109.
doi: 10.1002/prp2.109. Epub 2015 Jan 5. PubMed PMID: 25692026; PubMed Central
PMCID: PMC4317239.
<br>
4: Hase M, Babazono T, Ujihara N, Uchigata Y. Comparison of spironolactone and
trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction
of albuminuria in diabetic patients. J Diabetes Investig. 2013 May 6;4(3):316-9.
doi: 10.1111/jdi.12029. Epub 2013 Jan 24. PubMed PMID: 24843672; PubMed Central
PMCID: PMC4015670.
<br>
5: Nishihara M, Hirooka Y, Sunagawa K. Combining irbesartan and
trichlormethiazide enhances blood pressure reduction via inhibition of
sympathetic activity without adverse effects on metabolism in hypertensive rats
with metabolic syndrome. Clin Exp Hypertens. 2015;37(1):33-8. doi:
10.3109/10641963.2014.897719. Epub 2014 Mar 28. PubMed PMID: 24678944.
<br>
6: Ueda K, Makita N, Kawarazaki H, Fujiwara T, Unuma S, Monkawa T, Hayashi M,
Fujita T. A novel compound heterozygous mutation of Gitelman/’s syndrome in Japan,
as diagnosed by an extraordinary response of the fractional excretion rate of
chloride in the trichlormethiazide loading test. Intern Med. 2012;51(12):1549-53.
Epub 2012 Jun 15. PubMed PMID: 22728489.
<br>
7: Yoshii H, Mita T, Sato J, Kodama Y, Choi JB, Komiya K, Matsumoto K, Kanno R,
Kawasumi M, Koyano H, Hirose T, Onuma T, Kawamori R, Watada H. Comparison of
effects of azelnidipine and trichlormethiazide in combination with olmesartan on
blood pressure and metabolic parameters in hypertensive type 2 diabetic patients.
J Diabetes Investig. 2011 Nov 30;2(6):490-6. doi:
10.1111/j.2040-1124.2011.00135.x. PubMed PMID: 24843534; PubMed Central PMCID:
PMC4014909.
<br>
8: Takahashi Y, Nishida Y, Nakayama T, Asai S. Adverse effect profile of
trichlormethiazide: a retrospective observational study. Cardiovasc Diabetol.
2011 May 23;10:45. doi: 10.1186/1475-2840-10-45. PubMed PMID: 21605415; PubMed
Central PMCID: PMC3118327.
<br>
9: Sato K, Dohi Y, Kojima M, Takase H, Suzuki S, Ito S. Antioxidative effects of
thiazide diuretics in refractory hypertensive patients. A randomized crossover
trial of chlortalidone and trichlormethiazide. Arzneimittelforschung.
2010;60(10):612-6. PubMed PMID: 21125811.
<br>
10: Teraoka R, Matsushima Y, Sugimoto I, Inoue K, Morita SY, Kitagawa S. Effect
of pharmaceutical excipients on the stability of trichlormethiazide tablets under
humid conditions. Chem Pharm Bull (Tokyo). 2009 Dec;57(12):1343-7. PubMed PMID:
19952441.
|